Roche Holding AG (RHHBY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a subcutaneous (SC) formulation of Lunsumio for the treatment of adults with follicular lymphoma.
The CHMP opinion is based on the Phase II GO29781 study, in which subcutaneous Lunsumio demonstrated pharmacokinetic non-inferiority compared to intravenous administration, with no unexpected safety signals.
The company said that data from the Phase II GO29781 study have been submitted to health authorities worldwide, including the U.S. Food and Drug Administration(FDA), for approval consideration.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.